Dr. Daniel Lin, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 165
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Boston University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
PA license MD461067 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Thomas Jefferson University Hospital Philadelphia, PA
- Jefferson Stratford Hospital Stratford, NJ
- Jefferson Health- Northeast Philadelphia, PA
Medical groups
- Jefferson University Physicians (1,531 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 165
- Services billed
- 772
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 273 | 85 |
| Established patient office or other outpatient visit, 40-54 minutes | 86 | 54 |
| Established patient office or other outpatient visit, 20-29 minutes | 82 | 52 |
| New patient office or other outpatient visit, 60-74 minutes | 34 | 34 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | 11 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Philadelphia, PA | 60 |
| Ondansetron Hcl Other prescribers in Philadelphia, PA | 56 |
| Creon (lipase/protease/amylase) Other prescribers in Philadelphia, PA | 51 |
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 29 |
| Famotidine Other prescribers in Philadelphia, PA | 26 |
| Potassium Chloride Other prescribers in Philadelphia, PA | 17 |
| Cabometyx (cabozantinib s-malate) | 16 |
| Dicyclomine Hcl Other prescribers in Philadelphia, PA | 15 |
| Loperamide (loperamide hcl) Other prescribers in Philadelphia, PA | 13 |
| Lorazepam Other prescribers in Philadelphia, PA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $3,508 in total to this clinician.
| Incyte Corporation | $3,101 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $164 |
| AstraZeneca UK Limited | $135 |
| Genentech USA, Inc. | $92.18 |
| Teleflex LLC | $15.96 |
| Consulting Fee | $3,083 |
|---|---|
| Food and Beverage | $425 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $3,083 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $169,635 in research payments for these studies, mostly to the institutions running them.
- Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
Genentech, Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC
Genentech, Inc. - A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Exelixis Inc. - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie Inc. · Recruiting · NCT06858813
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.